Expertise in
2
conditions

Dr. Andrew Schreiber

Neurology
Andrew O Schreiber M D Inc.
1535 E 17th St Ste 101, 
Santa Ana, CA 
Expertise in
2
conditions
Andrew O Schreiber M D Inc.
1535 E 17th St Ste 101, 
Santa Ana, CA 

Overview

Andrew Schreiber is a Neurologist in Santa Ana, California. Dr. Schreiber is highly rated in 2 conditions, according to our data. His top areas of expertise are Narcolepsy, Excessive Daytime Sleepiness, Spinal Stenosis, and Herniated Disk.

His clinical research consists of participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Neurology

Licenses

Neurological Surgery in CA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

Andrew O Schreiber M D Inc.
1535 E 17th St Ste 101, Santa Ana, CA 92705

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Open Label Study of Safety/Tolerability of Once Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy Patients That Have and Have Not Been Previously Maintained on Twice-nightly Sodium Oxybate IR
Open Label Study of Safety/Tolerability of Once Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy Patients That Have and Have Not Been Previously Maintained on Twice-nightly Sodium Oxybate IR
Enrollment Status: Completed
Publish Date: October 02, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy
A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drug: SUVN-G3031
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 or Narcolepsy Type 2)
A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 or Narcolepsy Type 2)
Enrollment Status: Terminated
Publish Date: October 29, 2024
Intervention Type: Drug
Study Drug: TAK-994
Study Phase: Phase 2
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Phase: Phase 3
A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With Narcolepsy With Cataplexy (Narcolepsy Type 1)
A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With Narcolepsy With Cataplexy (Narcolepsy Type 1)
Enrollment Status: Terminated
Publish Date: December 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
Phase 2, Randomized, 3-Period, Placebo-Controlled Crossover Study to Evaluate the Efficacy and Safety in Obstructive Sleep Apnea of AD036 Versus Placebo or Atomoxetine
Phase 2, Randomized, 3-Period, Placebo-Controlled Crossover Study to Evaluate the Efficacy and Safety in Obstructive Sleep Apnea of AD036 Versus Placebo or Atomoxetine
Enrollment Status: Completed
Publish Date: September 14, 2023
Intervention Type: Drug
Study Phase: Phase 2
Phase 2, Placebo-Controlled, Parallel Group Dose-Finding Study to Evaluate the Efficacy and Safety of Three Dose Levels of AD036 in Adults With Obstructive Sleep Apnea
Phase 2, Placebo-Controlled, Parallel Group Dose-Finding Study to Evaluate the Efficacy and Safety of Three Dose Levels of AD036 in Adults With Obstructive Sleep Apnea
Enrollment Status: Completed
Publish Date: January 17, 2023
Intervention Type: Drug
Study Phase: Phase 2
Phase 2 Randomized Double-Blind Placebo-Controlled Parallel-Arm Dose Finding Study to Compare Fixed Dose Combinations of AD109 and AD504 to Atomoxetine or Placebo in Obstructive Sleep Apnea
Phase 2 Randomized Double-Blind Placebo-Controlled Parallel-Arm Dose Finding Study to Compare Fixed Dose Combinations of AD109 and AD504 to Atomoxetine or Placebo in Obstructive Sleep Apnea
Enrollment Status: Completed
Publish Date: December 12, 2022
Intervention Type: Drug
Study Drugs: AD109, AD504, Atomoxetine Hydrochloride
Study Phase: Phase 2
A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy
A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy
Enrollment Status: Completed
Publish Date: November 12, 2020
Intervention Type: Drug, Other
Study Phase: Phase 3
View 8 Less Clinical Trials
Similar Doctors
Expertise in
31
conditions
Dr. Tahseen Mozaffar
Neurology
Expertise in
31
conditions
Dr. Tahseen Mozaffar
Neurology

UC Irvine Medical Center

200 S Manchester Ave Ste 110, 
Orange, CA 
 (37.9 miles away)
714-456-2332
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dr. Tahseen Mozaffar is a Professor of Neurology, Orthopaedic Surgery and Pathology and Laboratory Medicine at University of California, Irvine. He is the Director of the UC Irvine-MDA ALS and Neuromuscular Center and the Director of the Division of Neuromuscular Diseases. Dr. Mozaffar serves as chair of one of the biomedical committees and the institutional liaison for Trials Innovation Hub for the Center for Translational Sciences Award (CTSA) at University of California, Irvine. He is the Principal Investigator for UCI-NEXT, the NeuroNEXT award to the University of California, Irvine, one of 25 such NeuroNEXT sites funded by the NINDS/NIH.. Dr. Mozaffar is highly rated in 31 conditions, according to our data. His top areas of expertise are Pompe Disease, Inclusion Body Myositis, Myositis, Myasthenia Gravis, and Thymectomy.

Expertise in
24
conditions
Dr. Daniela Bota
Neurology
Expertise in
24
conditions
Dr. Daniela Bota
Neurology

UCI Health

101 The City Dr S, 
Orange, CA 
 (37.2 miles away)
714-456-8000
Languages Spoken:
English
See accepted insurances

Daniela Bota is a Neurologist in Orange, California. Dr. Bota is highly rated in 24 conditions, according to our data. Her top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Namita Goyal
Expertise in
19
conditions
Dr. Namita Goyal
Neurology
Expertise in
19
conditions
Dr. Namita Goyal
Neurology

UC Irvine Medical Center

200 S Manchester Ave Ste 110, 
Orange, CA 
 (37.9 miles away)
714-456-2332
Languages Spoken:
English
See accepted insurances

Dr. Namita Goyal is a UCI Health neurologist with board certifications in neurology, electrodiagnostic medicine and neuromuscular medicine. Dr. Goyal is highly rated in 19 conditions, according to our data. Her top areas of expertise are Inclusion Body Myositis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Myositis, and Primary Lateral Sclerosis.

Frequently Asked Questions about Dr. Andrew Schreiber

How do I make an appointment with Dr. Andrew Schreiber?

You can book an appointment with Dr. Andrew Schreiber by calling their office at 714-834-1565. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Andrew Schreiber a top-rated expert for Narcolepsy?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Andrew Schreiber is classified as an Advanced expert for Narcolepsy, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Andrew Schreiber specialize in?

While Dr. Andrew Schreiber is a Neurology, they have specific expertise in Narcolepsy, Excessive Daytime Sleepiness, and Spinal Stenosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Andrew Schreiber accept my insurance?

Dr. Andrew Schreiber accepts most major insurance plans, including Aetna and Blue Shield of California. We recommend calling the office directly at 714-834-1565 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schreiber's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile